
This study hypothesized that adjusting the concentration of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for obesity could increase its clinical utility in the early diagnosis of acute heart failure (AHF). Among 2,038 patients, 509 (25%) were obese, of which 271 (53%) had AHF. The diagnostic accuracy of NT‐proBNP, as quantified by the area under the receiver‐operating characteristics curve, was lower in obese versus non‐obese patients (0.890 vs 0.938). Adjusting NT‐proBNP concentrations for obesity seems to increase its clinical utility in the early diagnosis of AHF.
Like
Save
Share